Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.